<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134390">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784679</url>
  </required_header>
  <id_info>
    <org_study_id>UX001-CL401</org_study_id>
    <nct_id>NCT01784679</nct_id>
  </id_info>
  <brief_title>Hereditary Inclusion Body Myopathy-Disease Monitoring (HIBM-DMP): A Combined Registry and Prospective Observational Natural History Study to Assess HIBM Disease</brief_title>
  <official_title>Hereditary Inclusion Body Myopathy-Patient Monitoring Program (HIBM-PMP): A Registry and Prospective Observational Natural History Study to Assess HIBM Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIBM is a severe progressive myopathy that typically presents in early adulthood as weakness
      in the distal muscles of the lower extremities and progresses proximally, leading to a loss
      of muscle strength and function, and ultimately a wheelchair-bound state. The rate of
      progression is gradual and variable over the course of 10-20 years or longer. There is a
      need to better understand the disease-specific features of HIBM to heighten disease
      awareness; facilitate early diagnosis; identify patients; expand knowledge of the clinical
      presentation, progression and variation of the disease; identify and validate biomarkers and
      other efficacy measures; inform on the design and interpretation of clinical studies of
      investigational products; and eventually to optimize patient management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this program is to better understand HIBM.

      The specific HIBM Disease Registry's objectives are to:

        -  Identify HIBM patients worldwide.

        -  Promote awareness and facilitate diagnosis of HIBM disease in the neuromuscular field.

        -  Obtain an assessment of the medical history, clinical presentation and progression of
           disease in HIBM patients and provide a connection for subjects to the broader HIBM
           community and associated programs.

        -  Provide customized information to subjects and their physicians that desire information
           on their disease status and progression.

      The specific HIBM Natural History Study's objectives are to:

        -  Characterize HIBM disease presentation and progression over time using relevant
           clinical assessments of muscle strength and function.

        -  Obtain information to better characterize quality of life and understand the timing of
           significant life changing events in HIBM patients using patient-reported outcomes.

        -  Identify biomarkers and efficacy measures for use as endpoints in future clinical
           studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Characterize HIBM disease presentation and progression over time using relevant clinical assessments of muscle strength and function.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obtain information to better characterize quality of life and understand the timing of significant life changing events in HIBM patients using patient-reported outcomes.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hereditary Inclusion Body Myopathy</condition>
  <condition>GNE Myopathy</condition>
  <condition>Nonaka Disease</condition>
  <condition>Quadriceps Sparing Myopathy (QSM)</condition>
  <condition>Distal Myopathy With Rimmed Vacuoles (DMRV)</condition>
  <arm_group>
    <arm_group_label>Natural History Prospective Observational Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Online Registry Patient Reported Group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Must have a diagnosis of HIBM, GNE myopathy, Quadriceps Sparing Myopathy (QSM), Inclusion
        Body Myopathy Type 2, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢ Must be at least 18 years of age.

               -  Must be willing and able to provide electronic consent to release access to
                  medical information to the study sponsor or its agents.

               -  Must have a diagnosis of HIBM, GNE myopathy, Quadriceps Sparing Myopathy (QSM),
                  Inclusion Body Myopathy Type 2, distal myopathy with rimmed vacuoles (DMRV), or
                  Nonaka disease.

               -  Must be willing and able to comply with all study requirements.

        Exclusion Criteria:

          -  For Natural History Component, Any unrelated, comorbid disease or condition that, in
             the view of the investigator, would interfere with study participation or would
             affect safety.

          -  For Online Registry Component, there are no exclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Ditton</last_name>
    <email>jditton@ultragenyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Minton</last_name>
      <phone>714-456-8520</phone>
      <email>bminton@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Tahseen Mozaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bulgarian Neuromuscular Disease Association</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivailo Tournev, MD</last_name>
      <phone>+359 2 9230670</phone>
      <email>itournev@emhpf.org</email>
    </contact>
    <investigator>
      <last_name>Ivailo Tournev, M.D., Ph.D., D. Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Hatcher</last_name>
      <phone>905-521-2100 X76929</phone>
      <email>hatchere@HHSC.CA</email>
    </contact>
    <investigator>
      <last_name>Mark Tarnopolsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Association Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Desbuleux</last_name>
      <phone>01-42-16-66-49</phone>
      <email>d.desbuleux@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Dr. Anthony Behin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne and Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana Pogoryelova</last_name>
      <phone>+44 (0) 191 2418640</phone>
      <email>Oksana.Pogoryelova@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Hanns Lochmuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://gnem-dmp.com</url>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Inclusion Body Myopathy</keyword>
  <keyword>GNE Myopathy</keyword>
  <keyword>Nonaka Disease</keyword>
  <keyword>Quadriceps Sparing Myopathy</keyword>
  <keyword>distal myopathy with rimmed vacuoles</keyword>
  <keyword>ultragenyx</keyword>
  <keyword>rare disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Distal Myopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
